We have built up an exciting portfolio of investments in high potential businesses across a range of therapeutic areas, technologies, geographies and clinical contexts.
18 October 2018
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas Crawford , CSCP, as Vice President, Supply Chain.
10 October 2018
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the appointment of Rolando Gutíerrez-Esteinou, M.D., as Vice President of Clinical Development and Pharmacovigilance where he will primarily be responsible for the medical leadership of our postpartum depression (PPD) programs and drug safety.